Alimera Sciences submits MAA for Iluvien to MHRA Alimera Sciences, Inc. Applications have also been submitted to the next other Concerned Member States in the European Union: Austria, France, Germany, Italy, Spain and Portugal. Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Great Start GeneticsDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixUsing integrated molecular pathology to manage incidental pancreatic cysts: an interview with Dr Ananya Das This MAA submission closely follows the submission of our NDA to the U dapoxetine .S. Food and Drug Administration the other day, and marks a significant first step toward the option of a sustained launch treatment for DME patients in Europe, said Dan Myers, cEO and president of Alimera.